October 2024
Sotigalimab may be a safe and feasible addition to the rectal cancer chemoradiotherapy paradigm
According to data from Dr. Aguilera's INNATE trial, sotigalimab addition to chemoradiotherapy in rectal cancer is safe, feasible, and shows higher pathological complete response rates compared to chemoradiotherapy alone.
INNATE trial news releaseAugust 2024
Basic Research: R01s – Drs. Todd Aguilera & You Zhang
Dr. Aguilera has received a five-year NIH R01 grant to develop advanced tools that integrate molecular, cellular, and spatial analysis to improve rectal cancer treatment by combining radiation, chemotherapy, and immunotherapy while reducing the need for surgery.
UT Southwestern news releaseAugust 2024
A Beacon of Hope in the Fight against Pancreatic Cancer
UT Southwestern’s Interdisciplinary Pancreatic Cancer Program, supported by Canopy Cancer Collective, is transforming care through a whole-person, team-based approach that delivers personalized, expert-guided support to improve survival and quality of life for patients facing one of the toughest cancer diagnoses.
UT Southwestern news releaseJanuary 2024
Drs. Aguilera and Elghonaimy named part of TMCi's 2024 Accelerator for Cancer Therapeutics cohort
Texas Medical Center Innovation (TMCi) has named Drs. Todd Aguilera and Eslam Elghonaimy as part of their 2024 Accelerator for Cancer Therapeutics cohort, which recognizes health tech innovators working on promising cancer therapeutics.
TMCi news releaseJune 2024
Can SBRT become more effective?
Researchers like Dr. Aguilera are exploring a promising combination of SBRT and the drug avasopasem to enhance tumor response and reduce side effects in pancreatic cancer patients, with early trials showing improved survival, tumor shrinkage, and surgical eligibility.
Let's Win news releaseJanuary 2024
Dr. Aguilera: We must educate and rethink
Dr. Aguilera comments on the 18-year gap in FDA approval for a drug combination with radiotherapy (RT).
OnCoDaily news releaseNovember 2023
UT Southwestern renewed as Amgen Scholar site with two-year grant
UT Southwestern will continue to offer undergraduate students exceptional hands-on research training opportunities, thanks to the recent extension of a grant from the Amgen Foundation.
UT Southwestern news releaseAugust 2023
Dr. Aguilera received White House-sponsored Cancer Moonshot award
Dr. Aguilera has been named one of 11 inaugural Cancer Moonshot Scholars. The national program recognizes a cohort of early-career investigators from underrepresented groups who have been identified as emerging leaders in cancer research and innovation.
Newswire press releaseSeptember 2022
What to Know - Pancreatic Cancer: Changing the Outlook
Dr. Aguilera discusses how early detection of pancreatic cancer can prove challenging, but UT Southwestern researchers are spearheading a unique effort to improve outcomes for these patients.
UT Southwestern What to Know videoAugust 2020
As someone who survived cancer as a young adult, Dr. Aguilera understands his patients' struggles
Dr. Aguilera is a cancer survivor who has dedicated his career to treating difficult cancers.
The Dallas Morning NewsJune 2020
Dr. Aguilera received Damon Runyon Award to study emerging immunotherapy
The Damon Runyon Cancer Research Foundation named Dr. Aguilera as one of four new Damon Runyon Clinical Investigators. The three-year, $600,000 award supports outstanding early career physician-scientists conducting patient-oriented cancer research with the potential to impact cancer diagnosis, prevention, and treatment.
Center TimesJuly 2021
Dr. Aguilera awarded SCCC Translational Pilot Award
Dr. Todd Aguilera, member of the Experimental Therapeutics Research Program, along with a multi-PI team, Andrew Jamieson, Ph.D., Assistant Professor of Bioinformatics; Ravikanth Maddipati, M.D., Assistant Professor of Internal Medicine, and Megan Wachsmann, M.D., Assistant Professor of Pathology, were awarded a SCCC Translational Pilot Award for “Interrogation of the Therapeutic Response in Pancreatic Adenocarcinoma to Identify Opportunities to Target the Tumor Immune Microenvironment.”
April 2018
Dr. Aguilera received Distinguished Researcher Award from UTSW President's Research Council
Distinguished Researcher AwardAugust 2017
Dr. Aguilera received the "CPRIT Recruitment of First-Time, Tenure-Track Faculty Member Award" for $2 million
Dr. Aguilera is working to develop new therapies that may work in conjunction with immune therapy to more effectively treat a significantly larger number of cancer patients.
CPRIT website